Skip Navigation


European Heart Journal Advance Access originally published online on September 8, 2006
European Heart Journal 2006 27(19):2257-2259; doi:10.1093/eurheartj/ehl249
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/19/2257    most recent
ehl249v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McMurray, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McMurray, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger

John McMurray*

Department of Cardiology, Western Infirmary, Glasgow G11 6NT, UK

* Corresponding author. Tel: +44 141 330 3479; fax: +44 141 330 6955. E-mail address: j.mcmurray@bio.gla.ac.uk

This editorial refers to ‘The perindopril in elderly people with chronic heart failure (PEP-CHF) study’{dagger} by J.G.F. Cleland et al., on page 2338

The first 10% of the full text of this article appears below.

Although up to half of all individuals with heart failure (HF) are said to have a preserved ejection fraction (HF-PEF), until recently only two sizeable, randomized placebo-controlled trials have been conducted in these patients (Tables 1 and 2).1–3 This small number compares with more than 20 trials in patients with a low EF. It is easy, therefore, to understand why the results of the Perindopril for Elderly People with Chronic Heart Failure (PEP-CHF) have been eagerly awaited.4,5


View this table:



  		Table 1 Large trials in HF-PEF

 

View this table:



  		Table 2 Baseline characteristics in trials of HF-PEF

 
. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

The perindopril in elderly people with chronic heart failure (PEP-CHF) study
John G.F. Cleland, Michal Tendera, Jerzy Adamus, Nick Freemantle, Lech Polonski, Jacqueline Taylor, and on behalf of PEP-CHF Investigators
EHJ 2006 27: 2338-2345. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
L. Groban, H. Jobe, M. Lin, T. Houle, D. A. Kitzman, and W. Sonntag
Effects of Short-Term Treadmill Exercise Training or Growth Hormone Supplementation on Diastolic Function and Exercise Tolerance in Old Rats
J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2008; 63(9): 911 - 920.
[Abstract] [Full Text] [PDF]

Home page
 Journal Watch CardiologyHome page
Perindopril Tested in HF Patients with Preserved Systolic Function
Journal Watch Cardiology, November 1, 2006; 2006(1101): 3 - 3.
[Full Text]